Deal-making among pharma firms expected to continue through 2014

04/30/2014 | Reuters

The flurry of acquisitions, sales and swaps among major pharmaceutical firms will continue unabated through the rest of the year, predicts Moody's Investors Service. The reasons include bolstering both branded and generic drug lines and lowering taxes. In addition to recent deals by Novartis, GlaxoSmithKline and Eli Lilly and Co., Merck & Co. is selling its consumer health care unit, and Pfizer continues to pursue a merger with AstraZeneca that could reap substantial tax rewards.

View Full Article in:


Published in Briefs: